MCID: SKN015
MIFTS: 71

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Skin Carcinoma

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 12 54 15 17
Skin Cancer 12 20 54 6 42 3 15
Melanoma and Non-Melanoma Skin Cancer 12
Malignant Neoplasm of Skin 12
Carcinoma of Skin 12
Ca - Skin Cancer 12
Cancer of Skin 12
Skin Cancers 15
Cancer, Skin 39

Classifications:



External Ids:

Disease Ontology 12 DOID:3451 DOID:4159
MeSH 44 D012878
NCIt 50 C2920 C4914
SNOMED-CT 67 94047004
UMLS 71 C0007114 C0699893

Summaries for Skin Carcinoma

MedlinePlus : 42 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Skin Carcinoma, also known as skin cancer, is related to squamous cell carcinoma and skin squamous cell carcinoma. An important gene associated with Skin Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Vemurafenib and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and prostate, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

CDC : 3 Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer-basal cell and squamous cell carcinomas-are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of cases of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

Related Diseases for Skin Carcinoma

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 852)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.3 TP53 STK11 PTEN PIK3CA MAP2K1 HRAS
2 skin squamous cell carcinoma 33.1 TP53 HRAS CDKN2A BRAF
3 prostate cancer 33.0 TP53 RAF1 PTEN PIK3CA PDGFRA MAP2K1
4 basal cell nevus syndrome 32.9 TP53 PTEN MC1R HRAS CTNNB1 AKT1
5 squamous cell carcinoma, head and neck 32.8 TP53 PTEN PIK3CA MAP2K1 HRAS CTNNB1
6 large congenital melanocytic nevus 32.8 NRAS MITF MC1R HRAS GNAQ GNA11
7 basal cell carcinoma 32.7 TP53 PTEN MC1R KIT CTNNB1 CDKN2A
8 acral lentiginous melanoma 32.7 PTEN NRAS MC1R KIT HRAS CDKN2A
9 cowden syndrome 32.6 TP53 STK11 PTEN PIK3CA HRAS CTNNB1
10 piebald trait 32.4 PDGFRA MITF MC1R KIT
11 lentigo maligna melanoma 32.3 MITF MC1R
12 melanoma, cutaneous malignant 1 32.0 TP53 STK11 RAF1 PTEN NRAS MITF
13 lentigines 31.8 RAF1 MC1R BRAF
14 melanoma 31.8 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
15 skin melanoma 31.8 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
16 dermatofibrosarcoma protuberans 31.7 TP53 PDGFRA KIT CDKN2A CDK4
17 lymphoma 31.6 TP53 PIK3CA KIT CDKN2A CDK4 BRAF
18 glioblastoma 31.6 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
19 lymphoma, non-hodgkin, familial 31.5 TP53 PIK3CA NRAS MAP2K1 BRAF AKT1
20 adenoid cystic carcinoma 31.4 TP53 PTEN PIK3CA KIT HRAS CTNNB1
21 keratosis 31.4 TP53 PIK3CA HRAS CDKN2A
22 merkel cell carcinoma 31.4 TP53 PDGFRA KIT CTNNB1 CDKN2A
23 adenocarcinoma 31.4 TP53 STK11 RAF1 PTEN PIK3CA MAP2K1
24 melanoma, uveal 31.4 TP53 RAF1 PTEN PIK3CA NRAS MITF
25 sarcoma 31.3 TP53 RAF1 PIK3CA PDGFRA NRAS KIT
26 nodular malignant melanoma 31.3 TP53 NRAS MITF MC1R KIT HRAS
27 myeloma, multiple 31.3 TP53 PTEN PIK3CA NRAS KIT HRAS
28 actinic keratosis 31.3 TP53 MITF MC1R HRAS CTNNB1 CDKN2A
29 lung cancer 31.3 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
30 small cell carcinoma 31.3 TP53 PTEN PDGFRA KIT CDKN2A
31 melanoma in congenital melanocytic nevus 31.3 RAF1 NRAS MITF MC1R KIT HRAS
32 li-fraumeni syndrome 31.2 TP53 STK11 PTEN PIK3CA HRAS CTNNB1
33 ovarian cancer 31.2 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
34 breast cancer 31.2 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
35 skin papilloma 31.2 TP53 PTEN HRAS AKT1
36 myeloid leukemia 31.2 TP53 RAF1 NRAS MAP2K1 KIT HRAS
37 leukemia, chronic myeloid 31.1 TP53 RAF1 PDGFRA NRAS KIT HRAS
38 cervical cancer 31.1 TP53 STK11 PTEN PIK3CA HRAS CTNNB1
39 leukemia, acute myeloid 31.1 TP53 PTEN PIK3CA PDGFRA NRAS MAP2K1
40 lung cancer susceptibility 3 31.1 TP53 STK11 RAF1 PIK3CA NRAS MAP2K1
41 medulloblastoma 31.1 TP53 PTEN PIK3CA PDGFRA NRAS MAP2K1
42 endometrial cancer 31.1 TP53 PTEN PIK3CA PDGFRA NRAS KIT
43 verrucous carcinoma 31.1 TP53 PTEN CDKN2A
44 neuroblastoma 31.1 TP53 PTEN PIK3CA NRAS MAP2K1 KIT
45 kidney cancer 31.1 TP53 PTEN PIK3CA CDKN2A AKT1
46 bladder cancer 31.1 TP53 PTEN PIK3CA NRAS MAP2K1 HRAS
47 renal cell carcinoma, nonpapillary 31.1 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
48 myelodysplastic syndrome 31.1 TP53 PTEN NRAS KIT HRAS CDKN2A
49 exanthem 31.0 KIT HRAS AKT1
50 nasopharyngeal carcinoma 31.0 TP53 PTEN PIK3CA NRAS HRAS CTNNB1

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma

Symptoms & Phenotypes for Skin Carcinoma

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

26 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.77 BRAF PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.77 BRAF PIK3CA HRAS
3 Decreased viability GR00107-A-1 10.77 MAP2K1
4 Decreased viability GR00173-A 10.77 PDGFRA
5 Decreased viability GR00221-A-1 10.77 AKT1 CDKN2A PDGFRA PIK3CA HRAS NRAS
6 Decreased viability GR00221-A-2 10.77 AKT1 PIK3CA HRAS RAF1
7 Decreased viability GR00221-A-3 10.77 AKT1 CDKN2A PDGFRA HRAS MAP2K1 NRAS
8 Decreased viability GR00221-A-4 10.77 AKT1 BRAF CDKN2A PDGFRA PIK3CA
9 Decreased viability GR00249-S 10.77 AKT1 BRAF PDGFRA
10 Decreased viability GR00301-A 10.77 BRAF KIT RAF1
11 Decreased viability GR00381-A-1 10.77 BRAF
12 Decreased viability GR00402-S-2 10.77 PDGFRA PIK3CA RAF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.45 KIT
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 10.45 CDK4
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.45 CDK4 PIK3CA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.45 PTEN
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.45 PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.45 AKT1 PIK3CA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.45 KIT
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.45 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.45 AKT1 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.45 KIT
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.45 PIK3CA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 10.45 CDK4
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.45 PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.45 AKT1 CDK4 KIT PIK3CA
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 10.45 CDK4
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.45 PIK3CA
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.45 AKT1
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.45 CDK4 PIK3CA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.45 CDK4
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.45 AKT1
33 Decreased substrate adherent cell growth GR00193-A-1 9.86 KIT
34 Decreased substrate adherent cell growth GR00193-A-2 9.86 CDK4 KIT
35 Decreased substrate adherent cell growth GR00193-A-3 9.86 BRAF CDK4
36 Decreased substrate adherent cell growth GR00193-A-4 9.86 BRAF CDK4 KIT
37 Decreased cell migration GR00055-A-1 9.77 AKT1 CDK4
38 Decreased cell migration GR00055-A-3 9.77 BRAF HRAS PIK3CA
39 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1
40 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.32 HRAS

MGI Mouse Phenotypes related to Skin Carcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.61 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
2 growth/size/body region MP:0005378 10.59 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
3 cardiovascular system MP:0005385 10.58 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
4 endocrine/exocrine gland MP:0005379 10.58 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
5 homeostasis/metabolism MP:0005376 10.57 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
6 cellular MP:0005384 10.55 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
7 integument MP:0010771 10.55 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
8 craniofacial MP:0005382 10.52 BRAF CDK4 CTNNB1 FBN1 GNA11 GNAQ
9 embryo MP:0005380 10.51 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
10 hematopoietic system MP:0005397 10.51 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
11 immune system MP:0005387 10.51 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
12 mortality/aging MP:0010768 10.49 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
13 nervous system MP:0003631 10.41 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
14 muscle MP:0005369 10.4 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
15 digestive/alimentary MP:0005381 10.39 BRAF CDK4 CDKN2A CTNNB1 HRAS KIT
16 neoplasm MP:0002006 10.38 AKT1 BRAF CDK4 CDKN2A CTNNB1 HRAS
17 liver/biliary system MP:0005370 10.34 AKT1 BRAF CDK4 CDKN2A CTNNB1 GNA11
18 limbs/digits/tail MP:0005371 10.31 BRAF CTNNB1 FBN1 GNA11 GNAQ KIT
19 normal MP:0002873 10.31 AKT1 BRAF CDK4 CTNNB1 GNA11 GNAQ
20 hearing/vestibular/ear MP:0005377 10.28 BRAF CTNNB1 GNA11 GNAQ KIT MAP2K1
21 no phenotypic analysis MP:0003012 10.25 CDKN2A CTNNB1 FBN1 HRAS KIT MC1R
22 pigmentation MP:0001186 10.21 BRAF CDK4 CDKN2A CTNNB1 FBN1 GNA11
23 renal/urinary system MP:0005367 10.13 BRAF CDK4 CTNNB1 FBN1 GNA11 GNAQ
24 reproductive system MP:0005389 10.1 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
25 respiratory system MP:0005388 10 AKT1 BRAF CDKN2A CTNNB1 FBN1 GNA11
26 skeleton MP:0005390 9.91 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
27 vision/eye MP:0005391 9.44 BRAF CDK4 CDKN2A CTNNB1 KIT MAP2K1

Drugs & Therapeutics for Skin Carcinoma

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
2
Ipilimumab Approved Phase 4 477202-00-9
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Aldesleukin Approved Phase 4 110942-02-4, 85898-30-2
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Azathioprine Approved Phase 4 446-86-6 2265
10
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
11 Immunosuppressive Agents Phase 4
12 Anti-Infective Agents Phase 4
13 Antimetabolites Phase 4
14 Antiviral Agents Phase 4
15 Immunologic Factors Phase 4
16 Neurotransmitter Agents Phase 4
17 Antirheumatic Agents Phase 4
18 Antineoplastic Agents, Immunological Phase 4
19 Dermatologic Agents Phase 4
20 Antifungal Agents Phase 4
21 Anti-HIV Agents Phase 4
22 Interleukin-2 Phase 4
23 Anti-Retroviral Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Anti-Bacterial Agents Phase 4
26 Cyclosporins Phase 4
27 Calcineurin Inhibitors Phase 4
28 abobotulinumtoxinA Phase 4
29 Hemagglutinins Phase 4
30 Botulinum Toxins, Type A Phase 4
31 Botulinum Toxins Phase 4
32 Agglutinins Phase 4
33 Cholinergic Agents Phase 4
34
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
35
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
36
Acetaminophen Approved Phase 3 103-90-2 1983
37
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
38
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
39
leucovorin Approved Phase 3 58-05-9 6006
40
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
41
Trametinib Approved Phase 3 871700-17-3 11707110
42 interferons Phase 3
43 Adjuvants, Immunologic Phase 3
44 Methyl 5-aminolevulinate Phase 3
45 Protective Agents Phase 2, Phase 3
46 Radiation-Protective Agents Phase 2, Phase 3
47 Antipyretics Phase 3
48 Sunscreening Agents Phase 3
49 Immunoglobulins Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 282)
# Name Status NCT ID Phase Drugs
1 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
2 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
3 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
4 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
5 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
6 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
7 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
8 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
9 A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
10 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
11 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
12 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
13 Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery Completed NCT00367042 Phase 2, Phase 3
14 A Randomized Control Trial of Sun Protection Interventions for Operating Engineers Completed NCT01804595 Phase 2, Phase 3
15 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
16 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
17 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
18 A Personalized Approach to Skin Cancer Prevention Among Adolescents Recruiting NCT04341064 Phase 3
19 A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) Active, not recruiting NCT03445533 Phase 3 Ipilimumab;IMO-2125;Ipilimumab
20 A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Active, not recruiting NCT02967692 Phase 3 Dabrafenib;Trametinib
21 Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial Active, not recruiting NCT04549675 Phase 3
22 Effect of Cryotherpy on Hypertrophic Scar Active, not recruiting NCT04532840 Phase 2, Phase 3
23 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
24 Transient Infrared Imaging for Early Detection of Skin Cancer Unknown status NCT02154451 Phase 1, Phase 2
25 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
26 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
27 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients. Unknown status NCT00829192 Phase 2 Afamelanotide (CUV1647);Placebo
28 Photochemical Tissue Bonding (PTB) for Excisional Wound Healing Completed NCT00586040 Phase 2
29 Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm Completed NCT00601640 Phase 2 Diclofenac Na gel;Eflornithine HCL ointment
30 Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma Completed NCT00295958 Phase 2
31 Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Completed NCT01327053 Phase 2 LDE225
32 Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma Completed NCT00715793 Phase 1, Phase 2 Decitabine;Temozolomide
33 Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients Completed NCT02347813 Phase 2 Pioglitazone
34 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma Completed NCT00847522 Phase 1, Phase 2 Fluorescein
35 Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Completed NCT00885534 Phase 2 Cisplatin, Vinblastine, Temozolomide
36 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
37 A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
38 Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms Completed NCT00021294 Phase 2 eflornithine;triamcinolone
39 A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients Completed NCT01359735 Phase 2
40 A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome Completed NCT00023621 Phase 2 celecoxib
41 A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
42 Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma Completed NCT01118091 Phase 2
43 A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin Completed NCT00126555 Phase 2 Gefitinib
44 A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses Completed NCT00002975 Phase 2 aminolevulinic acid
45 Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
46 Skin Cancer Prevention in a Pediatric Population Completed NCT01464957 Phase 2
47 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin Completed NCT00665470 Phase 2 Aldesleukin
48 A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer Completed NCT00089180 Phase 2 liposomal T4N5 lotion
49 Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR) Completed NCT00204789 Phase 2 Difluoromethylornithine
50 A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome Completed NCT00783965 Phase 2 tazarotene

Search NIH Clinical Center for Skin Carcinoma

Genetic Tests for Skin Carcinoma

Anatomical Context for Skin Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Carcinoma:

19
Skin

MalaCards organs/tissues related to Skin Carcinoma:

40
Skin, Kidney, Prostate, Breast, Lymph Node, T Cells, Thyroid

Publications for Skin Carcinoma

Articles related to Skin Carcinoma:

(show top 50) (show all 19559)
# Title Authors PMID Year
1
Usefulness of ultrasonography in determining the surgical excision margin in non-melanocytic skin cancer: A comparative analysis of preoperative ultrasonography and postoperative histopathology. 61 42
33371149 2020
2
In Brief: Hydrochlorothiazide and skin cancer. 42 61
33429413 2020
3
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
4
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
5
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
6
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
7
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
8
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
9
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013
10
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 6
23302800 2013
11
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6
22281684 2012
12
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 6
22113612 2011
13
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 6
21107320 2010
14
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 6
21107323 2010
15
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 6
20823850 2010
16
Inhibition of mutated, activated BRAF in metastatic melanoma. 6
20818844 2010
17
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 6
18398503 2008
18
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 6
17785355 2007
19
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 6
17488796 2007
20
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 6
17374713 2007
21
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 6
16772349 2006
22
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 6
16174717 2005
23
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 6
15998781 2005
24
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 6
16015629 2005
25
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
26
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 6
15687339 2005
27
Mutations of BRAF and RAS are rare events in germ cell tumours. 6
15386408 2005
28
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 6
15342696 2004
29
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 6
15356022 2004
30
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 6
15181070 2004
31
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 6
15126572 2004
32
BRAF T1796A transversion mutation in various thyroid neoplasms. 6
15001635 2004
33
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. 6
14513361 2003
34
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 6
14602780 2003
35
Exclusion of BRAFV599E as a melanoma susceptibility mutation. 6
12794760 2003
36
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
37
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 6
12670889 2003
38
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 6
12644542 2003
39
Absence of exon 15 BRAF germline mutations in familial melanoma. 6
12619120 2003
40
High frequency of BRAF mutations in nevi. 6
12447372 2003
41
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6
12198537 2002
42
Mutations of the BRAF gene in human cancer. 6
12068308 2002
43
Identification of PTEN mutations in metastatic melanoma specimens. 6
10978354 2000
44
Evaluation of the association between vitamin D and lung cancer skin metastasis: A protocol for systematic review. 42
33285703 2020
45
Signaling pathways in melanosome biogenesis and pathology. 61 54
20381640 2010
46
TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. 61 54
20399617 2010
47
Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. 61 54
20096264 2010
48
Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. 61 54
19818066 2010
49
Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. 61 54
20129839 2010
50
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. 54 61
20126537 2010

Variations for Skin Carcinoma

ClinVar genetic disease variations for Skin Carcinoma:

6 (show top 50) (show all 175)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN):c.649G>A (p.Val217Ile) SNV Pathogenic 7838 rs121909234 10:89717624-89717624 10:87957867-87957867
2 MAP2K1 NM_002755.3(MAP2K1):c.607G>A (p.Glu203Lys) SNV Pathogenic 375982 rs1057519733 15:66774131-66774131 15:66481793-66481793
3 NRAS NM_002524.5(NRAS):c.38G>C (p.Gly13Ala) SNV Pathogenic 375877 rs121434596 1:115258744-115258744 1:114716123-114716123
4 NRAS NM_002524.5(NRAS):c.181C>G (p.Gln61Glu) SNV Pathogenic 375875 rs121913254 1:115256530-115256530 1:114713909-114713909
5 BRAF NM_004333.6(BRAF):c.1779_1780delinsGA (p.Asp594Asn) Indel Pathogenic 375948 rs1057519718 7:140453155-140453156 7:140753355-140753356
6 MAP2K1 NM_002755.3(MAP2K1):c.790C>T (p.Pro264Ser) SNV Pathogenic 375983 rs1057519734 15:66777424-66777424 15:66485086-66485086
7 NRAS NM_002524.5(NRAS):c.182_183delinsGG (p.Gln61Arg) Indel Pathogenic 375873 rs1057519695 1:115256528-115256529 1:114713907-114713908
8 MAP2K1 NM_002755.3(MAP2K1):c.332T>G (p.Ile111Ser) SNV Pathogenic 375979 rs1057519730 15:66729124-66729124 15:66436786-66436786
9 MAP2K1 NM_002755.3(MAP2K1):c.157T>C (p.Phe53Leu) SNV Pathogenic 375977 rs1057519728 15:66727441-66727441 15:66435103-66435103
10 BRAF NM_004333.6(BRAF):c.1782T>A (p.Asp594Glu) SNV Pathogenic 375945 rs121913337 7:140453153-140453153 7:140753353-140753353
11 MAP2K1 NM_002755.4(MAP2K1):c.1144A>C (p.Asn382His) SNV Pathogenic 375984 rs1057519735 15:66782915-66782915 15:66490577-66490577
12 BRAF NM_004333.6(BRAF):c.1789_1790delinsTC (p.Leu597Ser) Indel Pathogenic 375942 rs121913368 7:140453145-140453146 7:140753345-140753346
13 NRAS NM_002524.5(NRAS):c.182_183delinsTG (p.Gln61Leu) Indel Pathogenic 375872 rs1057519695 1:115256528-115256529 1:114713907-114713908
14 BRAF NM_004333.6(BRAF):c.1798_1799delinsAA (p.Val600Lys) Indel Pathogenic 375941 rs121913227 7:140453136-140453137 7:140753336-140753337
15 BRAF NM_004333.6(BRAF):c.1799_1800delinsAT (p.Val600Asp) Indel Pathogenic 375939 rs121913377 7:140453135-140453136 7:140753335-140753336
16 BRAF NM_001374258.1(BRAF):c.1918G>A (p.Val640Met) SNV Pathogenic 44815 rs121913378 7:140453137-140453137 7:140753337-140753337
17 BRAF NM_004333.6(BRAF):c.1798_1799delinsAG (p.Val600Arg) Indel Pathogenic 375940 rs121913227 7:140453136-140453137 7:140753336-140753337
18 PTEN NM_000314.8(PTEN):c.633C>A SNV Pathogenic 7836 rs121909232 10:89712015-89712015 10:87952258-87952258
19 KIT NM_000222.2(KIT):c.1965T>A (p.Asn655Lys) SNV Pathogenic 375923 rs1057519708 4:55594262-55594262 4:54728096-54728096
20 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic 39648 rs121913237 1:115258747-115258747 1:114716126-114716126
21 NRAS NM_002524.5(NRAS):c.35G>T (p.Gly12Val) SNV Pathogenic 40470 rs121913237 1:115258747-115258747 1:114716126-114716126
22 NRAS NM_002524.5(NRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic 40471 rs121434595 1:115258745-115258745 1:114716124-114716124
23 KIT NM_000222.2(KIT):c.1676T>A (p.Val559Asp) SNV Pathogenic 13856 rs121913517 4:55593610-55593610 4:54727444-54727444
24 KIT NM_000222.2(KIT):c.1676T>G (p.Val559Gly) SNV Pathogenic 375912 rs121913517 4:55593610-55593610 4:54727444-54727444
25 KIT NM_000222.2(KIT):c.1669T>A (p.Trp557Arg) SNV Pathogenic 375908 rs121913235 4:55593603-55593603 4:54727437-54727437
26 KIT NM_000222.2(KIT):c.1679T>A (p.Val560Asp) SNV Pathogenic 375914 rs121913521 4:55593613-55593613 4:54727447-54727447
27 KIT NM_000222.2(KIT):c.2485G>C (p.Ala829Pro) SNV Pathogenic 375933 rs1057519713 4:55602664-55602664 4:54736498-54736498
28 KIT NM_000222.2(KIT):c.1679T>G (p.Val560Gly) SNV Pathogenic 375916 rs121913521 4:55593613-55593613 4:54727447-54727447
29 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic 13899 rs121434595 1:115258745-115258745 1:114716124-114716124
30 GNAQ NM_002072.5(GNAQ):c.626A>C (p.Gln209Pro) SNV Pathogenic 375957 rs121913492 9:80409488-80409488 9:77794572-77794572
31 GNA11 NM_002067.5(GNA11):c.626A>T (p.Gln209Leu) SNV Pathogenic 376002 rs1057519742 19:3118942-3118942 19:3118944-3118944
32 GNA11 NM_002067.5(GNA11):c.626A>C (p.Gln209Pro) SNV Pathogenic 376001 rs1057519742 19:3118942-3118942 19:3118944-3118944
33 KIT NM_000222.2(KIT):c.1727T>C (p.Leu576Pro) SNV Pathogenic 375919 rs121913513 4:55593661-55593661 4:54727495-54727495
34 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly) SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
35 GNAQ NM_002072.5(GNAQ):c.626A>T (p.Gln209Leu) SNV Pathogenic 375955 rs121913492 9:80409488-80409488 9:77794572-77794572
36 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr) SNV Pathogenic 375895 rs121913409 3:41266137-41266137 3:41224646-41224646
37 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val) SNV Pathogenic 375876 rs121434596 1:115258744-115258744 1:114716123-114716123
38 KIT NM_000222.2(KIT):c.1650A>T (p.Lys550Asn) SNV Pathogenic 375906 rs1057519703 4:55593584-55593584 4:54727418-54727418
39 BRAF NM_001374258.1(BRAF):c.1909C>G (p.Leu637Val) SNV Pathogenic 13969 rs121913369 7:140453146-140453146 7:140753346-140753346
40 KIT NM_000222.2(KIT):c.1961T>C (p.Val654Ala) SNV Pathogenic 375921 rs121913523 4:55594258-55594258 4:54728092-54728092
41 KIT NM_000222.2(KIT):c.2458G>C (p.Asp820His) SNV Pathogenic 375927 rs1057519710 4:55599332-55599332 4:54733166-54733166
42 KIT NM_000222.2(KIT):c.1965T>G (p.Asn655Lys) SNV Pathogenic 375924 rs1057519708 4:55594262-55594262 4:54728096-54728096
43 BRAF NM_004333.6(BRAF):c.1782T>G (p.Asp594Glu) SNV Pathogenic 375944 rs121913337 7:140453153-140453153 7:140753353-140753353
44 KIT NM_000222.3(KIT):c.2446G>C SNV Pathogenic 13863 rs121913506 4:55599320-55599320 4:54733154-54733154
45 KIT NM_000222.3(KIT):c.2466T>G SNV Pathogenic 375932 rs121913514 4:55599340-55599340 4:54733174-54733174
46 BRAF NM_001374258.1(BRAF):c.1910T>A (p.Leu637Gln) SNV Pathogenic 76687 rs121913366 7:140453145-140453145 7:140753345-140753345
47 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
48 NRAS NM_002524.5(NRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic 177778 rs121913250 1:115258748-115258748 1:114716127-114716127
49 KIT NM_000222.2(KIT):c.1679T>C (p.Val560Ala) SNV Pathogenic 375915 rs121913521 4:55593613-55593613 4:54727447-54727447
50 KIT NM_000222.2(KIT):c.1510T>C (p.Phe504Leu) SNV Pathogenic 375904 rs1057519702 4:55592186-55592186 4:54726020-54726020

Cosmic variations for Skin Carcinoma:

9 (show top 50) (show all 2121)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM152022165 YES1 skin,eye,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 48
2 COSM136837388 YES1 skin,eye,carcinoma,squamous cell carcinoma c.866G>A p.G289E 18:743289-743289 48
3 COSM89895645 YES1 skin,eye,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 48
4 COSM150677496 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2050C>T p.R684C 9:132903794-132903794 48
5 COSM85720102 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
6 COSM149039828 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2062C>T p.R688C 9:132903794-132903794 48
7 COSM150537076 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.1912C>T p.R638C 9:132903794-132903794 48
8 COSM151334154 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
9 COSM111041127 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
10 COSM147983627 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2062C>T p.R688C 9:132903794-132903794 48
11 COSM148035069 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2047C>T p.R683C 9:132903794-132903794 48
12 COSM151875202 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
13 COSM133087519 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.1912C>T p.R638C 9:132903794-132903794 48
14 COSM90145852 TRAF7 skin,eye,carcinoma,squamous cell carcinoma c.349G>A p.E117K 16:2171264-2171264 48
15 COSM106059757 TP53 skin,hand,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 48
16 COSM143944147 TP53 skin,arm,carcinoma,squamous cell carcinoma c.265C>T p.R89W 17:7674221-7674221 48
17 COSM112354551 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 48
18 COSM112254631 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 48
19 COSM111759858 TP53 skin,hand,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 48
20 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 48
21 COSM121875437 TP53 skin,face,carcinoma,squamous cell carcinoma c.178C>T p.Q60* 17:7674957-7674957 48
22 COSM143388508 TP53 skin,face,carcinoma,squamous cell carcinoma c.629G>C p.R210T 17:7674217-7674217 48
23 COSM111758868 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 48
24 COSM142560384 TP53 skin,face,carcinoma,squamous cell carcinoma c.616G>T p.G206C 17:7674230-7674230 48
25 COSM145161899 TP53 skin,hand,carcinoma,squamous cell carcinoma c.833A>G p.Q278R 17:7673578-7673578 48
26 COSM144021997 TP53 skin,face,carcinoma,squamous cell carcinoma c.421C>T p.P141S 17:7675158-7675158 48
27 COSM144020497 TP53 skin,eye,carcinoma,squamous cell carcinoma c.806G>C p.R269T 17:7673781-7673781 48
28 COSM144658487 TP53 skin,face,carcinoma,squamous cell carcinoma c.143C>A p.P48Q 17:7676109-7676109 48
29 COSM142639459 TP53 skin,face,carcinoma,squamous cell carcinoma c.597T>A p.C199* 17:7674249-7674249 48
30 COSM105620390 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 48
31 COSM112254266 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 48
32 COSM112283184 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 48
33 COSM112263720 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 48
34 COSM144313019 TP53 skin,eye,carcinoma,squamous cell carcinoma c.470G>T p.R157L 17:7674944-7674944 48
35 COSM93239210 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 48
36 COSM145019215 TP53 skin,hand,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7673764-7673764 48
37 COSM105620642 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 48
38 COSM143949062 TP53 skin,face,carcinoma,squamous cell carcinoma c.263A>C p.N88T 17:7674223-7674223 48
39 COSM111775215 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 48
40 COSM122740947 TP53 skin,eye,carcinoma,squamous cell carcinoma c.443G>C p.R148T 17:7673781-7673781 48
41 COSM144129318 TP53 skin,face,carcinoma,squamous cell carcinoma c.229T>C p.Y77H 17:7674257-7674257 48
42 COSM144088618 TP53 skin,face,carcinoma,squamous cell carcinoma c.160C>T p.R54* 17:7674894-7674894 48
43 COSM87910628 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 48
44 COSM144662686 TP53 skin,face,carcinoma,squamous cell carcinoma c.715C>T p.P239S 17:7673788-7673788 48
45 COSM144650676 TP53 skin,face,carcinoma,squamous cell carcinoma c.457C>T p.Q153* 17:7674957-7674957 48
46 COSM142560553 TP53 skin,face,carcinoma,squamous cell carcinoma c.625C>T p.R209W 17:7674221-7674221 48
47 COSM144309924 TP53 skin,hand,carcinoma,squamous cell carcinoma c.701G>A p.R234H 17:7673802-7673802 48
48 COSM93194159 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 48
49 COSM142560281 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 48
50 COSM122737048 TP53 skin,eye,carcinoma,squamous cell carcinoma c.191G>T p.R64L 17:7674944-7674944 48

Expression for Skin Carcinoma

Search GEO for disease gene expression data for Skin Carcinoma.

Pathways for Skin Carcinoma

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.38 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
2
Show member pathways
14.21 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
3
Show member pathways
14.06 TP53 RAF1 PTEN PDGFRA NRAS MAP2K1
4
Show member pathways
14.03 TP53 STK11 RAF1 PTEN PDGFRA NRAS
5
Show member pathways
13.93 TP53 RAF1 PDGFRA NRAS MAP2K1 KIT
6
Show member pathways
13.9 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
7
Show member pathways
13.87 TP53 RAF1 PDGFRA NRAS MAP2K1 KIT
8
Show member pathways
13.77 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
9
Show member pathways
13.77 TP53 RAF1 PIK3CA PDGFRA NRAS MAP2K1
10
Show member pathways
13.74 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
11
Show member pathways
13.68 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
12
Show member pathways
13.65 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
13
Show member pathways
13.65 RAF1 PTEN PIK3CA NRAS MAP2K1 HRAS
14
Show member pathways
13.62 TP53 RAF1 PTEN PDGFRA NRAS KIT
15
Show member pathways
13.6 TP53 RAF1 PIK3CA PDGFRA NRAS MAP2K1
16
Show member pathways
13.55 RAF1 PTEN PDGFRA NRAS MAP2K1 KIT
17
Show member pathways
13.51 TP53 RAF1 PIK3CA NRAS HRAS GNAQ
18
Show member pathways
13.51 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
19
Show member pathways
13.46 PTEN PDGFRA NRAS KIT HRAS CTNNB1
20
Show member pathways
13.46 TP53 RAF1 PTEN NRAS MAP2K1 HRAS
21
Show member pathways
13.34 TP53 RAF1 PTEN PIK3CA NRAS MAP2K1
22
Show member pathways
13.32 TP53 RAF1 PTEN PDGFRA NRAS MAP2K1
23
Show member pathways
13.31 STK11 RAF1 PDGFRA NRAS MAP2K1 KIT
24
Show member pathways
13.3 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
25
Show member pathways
13.29 RAF1 NRAS MAP2K1 HRAS GNA11 CTNNB1
26
Show member pathways
13.26 TP53 PTEN PIK3CA PDGFRA KIT AKT1
27
Show member pathways
13.25 TP53 RAF1 NRAS MAP2K1 HRAS GNA11
28
Show member pathways
13.19 RAF1 PTEN NRAS MAP2K1 HRAS CTNNB1
29
Show member pathways
13.18 RAF1 PTEN PIK3CA PDGFRA NRAS MAP2K1
30
Show member pathways
13.16 RAF1 PTEN PIK3CA NRAS MAP2K1 HRAS
31
Show member pathways
13.16 RAF1 PIK3CA NRAS MAP2K1 HRAS GNAQ
32
Show member pathways
13.14 TP53 RAF1 PDGFRA NRAS MAP2K1 HRAS
33
Show member pathways
13.14 RAF1 PTEN PIK3CA PDGFRA NRAS MAP2K1
34
Show member pathways
13.14 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
35
Show member pathways
13.08 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
36
Show member pathways
13.07 RAF1 NRAS MAP2K1 HRAS GNA11 CTNNB1
37 13.05 TP53 RAF1 PDGFRA NRAS MAP2K1 KIT
38
Show member pathways
13.02 TP53 RAF1 PIK3CA MAP2K1 CDK4 AKT1
39
Show member pathways
13.02 RAF1 PTEN PIK3CA MAP2K1 HRAS BRAF
40
Show member pathways
13.01 PIK3CA NRAS MAP2K1 HRAS GNAQ GNA11
41
Show member pathways
13 TP53 PTEN PIK3CA PDGFRA NRAS KIT
42
Show member pathways
12.99 TP53 RAF1 PTEN PIK3CA NRAS MAP2K1
43
Show member pathways
12.98 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
44
Show member pathways
12.98 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
45
Show member pathways
12.98 TP53 RAF1 PIK3CA PDGFRA NRAS MAP2K1
46
Show member pathways
12.95 RAF1 PIK3CA MAP2K1 HRAS CTNNB1 AKT1
47
Show member pathways
12.95 RAF1 PIK3CA NRAS MAP2K1 HRAS GNAQ
48
Show member pathways
12.94 TP53 RAF1 PDGFRA NRAS MAP2K1 HRAS
49
Show member pathways
12.93 RAF1 NRAS MAP2K1 HRAS GNA11 BRAF
50
Show member pathways
12.93 RAF1 PIK3CA NRAS MAP2K1 HRAS GNAQ

GO Terms for Skin Carcinoma

Cellular components related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.22 TP53 STK11 RAF1 PIK3CA PDGFRA NRAS
2 plasma membrane GO:0005886 10 RAF1 PTEN PIK3CA PDGFRA NRAS MC1R
3 mitochondrion GO:0005739 9.86 TP53 STK11 RAF1 PTEN MAP2K1 CDKN2A
4 cytoplasm GO:0005737 9.58 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
5 protein-containing complex GO:0032991 9.5 TP53 PDGFRA MITF CTNNB1 CDKN2A CDK4

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TP53 RAF1 MITF MC1R HRAS CTNNB1
2 signal transduction GO:0007165 10.18 RAF1 NRAS MC1R MAP2K1 KIT HRAS
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TP53 MITF MAP2K1 CTNNB1 CDKN2A AKT1
4 apoptotic process GO:0006915 10.13 TP53 STK11 RAF1 PTEN HRAS CDKN2A
5 intracellular signal transduction GO:0035556 10.11 RAF1 MC1R KIT BRAF AKT1
6 positive regulation of cell proliferation GO:0008284 10.08 PTEN PDGFRA KIT HRAS CTNNB1 CDK4
7 negative regulation of apoptotic process GO:0043066 10.07 TP53 RAF1 PTEN MITF CTNNB1 BRAF
8 negative regulation of gene expression GO:0010629 10.05 TP53 MAP2K1 HRAS CTNNB1 AKT1
9 positive regulation of apoptotic process GO:0043065 10.03 TP53 PTEN CTNNB1 CDKN2A CDK4 AKT1
10 protein stabilization GO:0050821 10 TP53 PTEN GNAQ CDKN2A
11 positive regulation of protein kinase B signaling GO:0051897 9.99 PIK3CA PDGFRA MC1R KIT
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 PTEN PDGFRA MAP2K1 HRAS BRAF
13 T cell receptor signaling pathway GO:0050852 9.98 STK11 PIK3CA HRAS BRAF
14 protein autophosphorylation GO:0046777 9.98 STK11 PDGFRA KIT AKT1
15 peptidyl-tyrosine phosphorylation GO:0018108 9.96 PDGFRA MAP2K1 KIT BRAF
16 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 PTEN KIT CTNNB1 AKT1
17 platelet activation GO:0030168 9.93 RAF1 PIK3CA GNAQ GNA11
18 negative regulation of cell proliferation GO:0008285 9.92 TP53 STK11 RAF1 PTEN MAP2K1 HRAS
19 regulation of cell proliferation GO:0042127 9.91 TP53 MITF KIT CTNNB1 CDK4 BRAF
20 MAPK cascade GO:0000165 9.91 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
21 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 RAF1 PIK3CA BRAF AKT1
22 canonical Wnt signaling pathway GO:0060070 9.89 STK11 PTEN CTNNB1
23 cell cycle arrest GO:0007050 9.89 TP53 STK11 MAP2K1 HRAS CDKN2A
24 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.88 PTEN CDKN2A CDK4
25 somatic stem cell population maintenance GO:0035019 9.88 RAF1 KIT BRAF
26 hematopoietic progenitor cell differentiation GO:0002244 9.88 TP53 PDGFRA KIT
27 Ras protein signal transduction GO:0007265 9.87 TP53 NRAS HRAS CDKN2A
28 epidermal growth factor receptor signaling pathway GO:0007173 9.85 PIK3CA BRAF AKT1
29 cellular response to nerve growth factor stimulus GO:1990090 9.85 PTEN BRAF AKT1
30 protein kinase B signaling GO:0043491 9.84 PTEN PIK3CA AKT1
31 phosphatidylinositol 3-kinase signaling GO:0014065 9.84 PTEN PIK3CA AKT1
32 positive regulation of axonogenesis GO:0050772 9.83 STK11 MAP2K1 BRAF
33 pigmentation GO:0043473 9.82 MITF MC1R KIT
34 positive regulation of protein localization to nucleus GO:1900182 9.82 STK11 CDKN2A AKT1
35 protein phosphorylation GO:0006468 9.81 STK11 RAF1 PIK3CA PDGFRA MAP2K1 KIT
36 vasculature development GO:0001944 9.8 STK11 PIK3CA CTNNB1
37 heart development GO:0007507 9.8 TP53 RAF1 PTEN MAP2K1 GNA11 FBN1
38 cellular senescence GO:0090398 9.79 MAP2K1 HRAS CDKN2A
39 thyroid gland development GO:0030878 9.78 RAF1 MAP2K1 BRAF
40 thymus development GO:0048538 9.78 RAF1 MAP2K1 CTNNB1 BRAF
41 face development GO:0060324 9.75 RAF1 MAP2K1 BRAF
42 developmental pigmentation GO:0048066 9.72 KIT GNA11
43 negative regulation of cell size GO:0045792 9.72 PTEN AKT1
44 cellular response to insulin-like growth factor stimulus GO:1990314 9.72 PTEN FBN1
45 somatic stem cell division GO:0048103 9.72 KIT CDKN2A
46 positive regulation of phospholipase C activity GO:0010863 9.72 PDGFRA KIT HRAS
47 phototransduction, visible light GO:0007603 9.71 GNAQ GNA11
48 positive regulation of DNA-templated transcription, initiation GO:2000144 9.7 MITF CTNNB1
49 entrainment of circadian clock GO:0009649 9.7 GNAQ GNA11
50 trachea formation GO:0060440 9.69 MAP2K1 CTNNB1

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.4 TP53 STK11 RAF1 PTEN PIK3CA PDGFRA
2 transferase activity GO:0016740 10.13 STK11 RAF1 PIK3CA PDGFRA MAP2K1 KIT
3 ATP binding GO:0005524 10.07 TP53 STK11 RAF1 PIK3CA PDGFRA MAP2K1
4 protein kinase binding GO:0019901 9.95 TP53 PTEN CTNNB1 CDKN2A AKT1
5 enzyme binding GO:0019899 9.91 TP53 RAF1 PTEN CTNNB1 AKT1
6 protein serine/threonine kinase activity GO:0004674 9.87 STK11 RAF1 PIK3CA MAP2K1 CDK4 BRAF
7 protein-containing complex binding GO:0044877 9.8 RAF1 PDGFRA NRAS HRAS FBN1 CDK4
8 nucleotide binding GO:0000166 9.77 STK11 RAF1 PIK3CA PDGFRA NRAS MAP2K1
9 protein kinase activity GO:0004672 9.76 STK11 RAF1 PDGFRA MAP2K1 KIT CDK4
10 protein tyrosine kinase activity GO:0004713 9.73 PDGFRA MAP2K1 KIT BRAF
11 p53 binding GO:0002039 9.7 TP53 STK11 CDKN2A
12 disordered domain specific binding GO:0097718 9.63 TP53 CTNNB1 CDKN2A
13 MDM2/MDM4 family protein binding GO:0097371 9.54 TP53 CDKN2A
14 type 2A serotonin receptor binding GO:0031826 9.49 GNAQ GNA11
15 kinase activity GO:0016301 9.32 STK11 RAF1 PIK3CA PDGFRA MAP2K1 KIT

Sources for Skin Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....